V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 270018439 | 270010343 | 1.62 | 54.4 | Curative (C) | 2014-09-14 | 2014-09-14 | PEMBROLIZUMAB | N | N | 270020111 | IBRUTINIB |
| 270018440 | 270014829 | null | 97.3 | Disease modification (D) | 2015-05-31 | 2015-08-23 | IRINOTECAN + MDG + PANITUMUMAB | N | N | 270020119 | MITOMYCIN INTRAVESICULAR |
| 270018441 | 270017179 | 1.78 | 51.9 | Adjuvant (A) | 2019-09-30 | 2019-10-07 | CARBOPLATIN + FLUOROURACIL | 2 | N | 270020188 | BEVACIZUMAB + IRINOTECAN + MDG |
| 270018442 | 270010350 | 1.63 | 44.4 | Palliative (P) | 2017-02-01 | 2017-08-17 | Pemetrexed | 02 | N | 270020201 | DOCETAXEL |
| 270018443 | 270010353 | 1.59 | 67.9 | Curative (C) | 2013-10-12 | 2013-10-13 | R GDP | 02 | N | 270020227 | Y-90 |
| 270018444 | 270010355 | 1.82 | 101 | Disease modification (D) | null | 2015-12-20 | R-GDP | N | null | 270020297 | GDP R |
| 270018445 | 270014836 | null | 71.7 | Palliative (P) | 2017-04-17 | 2017-04-17 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | N | null | 270020347 | GDP R |
| 270018446 | 270014840 | 1.68 | 113 | Adjuvant (A) | 2014-12-10 | 2014-12-18 | GEMCITABINE + OXALIPLATIN + RITUXIMAB | N | N | 270020411 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE |
| 270018447 | 270017186 | 1.71 | 78.7 | null | 2018-01-14 | 2018-01-15 | CYTARABINE + Vosaroxin | 2 | N | 270020545 | ETOPOSIDE |
| 270018448 | 270014845 | 1.72 | 91.8 | Palliative (P) | 2017-08-18 | 2017-08-18 | Gemcitabine + Vinorelbine IV | 2 | N | 270020549 | POMALIDOMIDE |
| 270018449 | 270014846 | 1.8 | 53.4 | Curative (C) | 2016-12-26 | 2017-03-06 | CARBOPLATIN + GEMCITABINE | N | N | 270020593 | GEMCARBO |
| 270018450 | 270010376 | 1.51 | null | Palliative (P) | 2013-07-07 | 2013-07-16 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | N | null | 270020635 | RATHL TRIAL |
| 270018451 | 270010380 | null | null | Palliative (P) | 2014-01-19 | 2014-02-20 | ICE | N | N | 270020640 | CVP R |
| 270018452 | 270010381 | null | 101 | null | 2015-10-14 | 2015-10-30 | Methotrexate intrathecal | N | N | 270020661 | BLEOMYCIN |
| 270018453 | 270014851 | 1.7 | 51.2 | Palliative (P) | 2018-03-15 | 2018-04-01 | NHL 2003 Gp B COP | N | N | 270020719 | CYCLOPHOSPHAMIDE |
| 270018454 | 270010389 | 1.75 | 80.6 | Curative (C) | 2018-08-19 | 2018-08-22 | CHLVPP PABLOE | 02 | N | 270020741 | HYDROXYCARBAMIDE |
| 270018455 | 270014853 | 1.64 | null | Adjuvant (A) | 2014-02-06 | 2014-02-08 | Docetaxel | 2 | N | 270020762 | CYCLOPHOSPHAMIDE |
| 270018456 | 270010395 | 1.6 | 69.8 | Curative (C) | 2017-05-21 | 2017-07-17 | NHL 2003 Gp B CYM 1 & 2 | 02 | Y | 270020775 | CTD |
| 270018457 | 270019715 | 1.65 | 112.3 | Neo-adjuvant (N) | 2013-07-30 | 2013-12-23 | RATHL TRIAL | 02 | N | 270020781 | CHLORAMBUCIL + ETOPOSIDE + LOMUSTINE |
| 270018458 | 270018526 | 1.7 | 58 | Curative (C) | 2017-09-11 | 2017-11-21 | ICE + GCSF | Y | N | 270020899 | R CODOX-M/ R IVAC |
| 270018459 | 270010404 | 1.72 | 87 | Curative (C) | 2018-01-30 | 2018-02-11 | NHL 2003 Gp B COP | 02 | N | 270021016 | Y-90 |
| 270018460 | 270010406 | 1.67 | 86 | null | 2018-05-25 | 2018-05-25 | Fludarabine + Melphalan RIC Allo | N | N | 270021045 | CISPLATIN + ETOPOSIDE |
| 270018461 | 270010410 | null | null | Palliative (P) | 2018-01-26 | 2018-07-17 | Hydroxycarbamide | N | N | 270021079 | HYDROXYCARBAMIDE |
| 270018462 | 270010429 | 1.66 | 60.6 | Palliative (P) | null | 2015-06-10 | CVP R | 2 | N | 270021486 | ECHELON 1 TRIAL |
| 270018463 | 270010433 | null | null | Palliative (P) | 2019-06-25 | 2019-06-25 | ICE | N | N | 270021516 | CHLORAMBUCIL + ETOPOSIDE + LOMUSTINE |
| 270018464 | 270017205 | 1.62 | 48 | Curative (C) | null | 2017-12-30 | GEMCITABINE + VINORELBINE | 01 | N | 270021549 | RATHL TRIAL |
| 270018465 | 270010436 | 1.77 | 94.5 | Curative (C) | 2018-10-05 | 2018-10-05 | RUXOLITINIB | 01 | N | 270021605 | CHLORAMBUCIL + RITUXIMAB |
| 270018466 | 270010443 | 1.75 | 84.2 | Curative (C) | null | 2014-09-30 | R-GEM-P | null | N | 270021799 | DACARBAZINE + DOXORUBICIN + VINBLASTINE |
| 270018467 | 270019718 | 1.86 | 84.5 | Palliative (P) | 2017-03-02 | 2017-03-10 | NHL 2003 Gp B COPADM 1 & 2 | 2 | N | 270021829 | ICE |
| 270018468 | 270010446 | 1.63 | 48.7 | Curative (C) | 2016-04-27 | 2016-09-30 | Hydroxycarbamide | N | N | 270021842 | DOXORUBICIN |
| 270018469 | 270010450 | 1.63 | null | Palliative (P) | 2017-08-04 | 2017-08-11 | BOSUTINIB | N | N | 270021910 | BENDAMUSTINE + CYTARABINE + ETOPOSIDE + MELPHALAN |
| 270018470 | 270010460 | null | null | Curative (C) | null | 2018-01-22 | DA-EPOCH-R | null | null | 270022133 | GEMCARBO |
| 270018471 | 270010462 | 1.65 | 57.9 | Curative (C) | 2016-08-22 | 2016-08-22 | CYCLOPHOSPHAMIDE + DACARBAZINE + VINCRISTINE | N | N | 270022153 | ICE-R |
| 270018472 | 270010464 | null | 87.1 | Palliative (P) | 2014-10-09 | 2014-10-16 | Bortezomib + Panobinostat | N | N | 270022158 | PACLITAXEL |
| 270018473 | 270010465 | 1.81 | 92.2 | Not known (9) | 2018-05-30 | 2018-05-31 | DACARBAZINE + DOXORUBICIN + VINBLASTINE | N | N | 270022215 | GEMCARBO |
| 270018474 | 270010471 | 1.69 | 90.4 | Curative (C) | 2015-12-06 | 2015-12-20 | CHLVPP PABLOE | 02 | N | 270022247 | ESHAP R |
| 270018475 | 270010475 | 1.71 | 98.9 | Curative (C) | 2014-08-17 | 2014-08-20 | Bendamustine+Rituximab(Sub Courses) | 02 | null | 270022283 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 270018476 | 270010480 | 1.7 | 59 | Curative (C) | 2016-03-05 | 2016-10-20 | ICE (no GCSF) | null | null | 270022325 | CYTARABINE + OXALIPLATIN |
| 270018477 | 270010482 | 1.82 | 105 | Disease modification (D) | 2016-11-27 | 2016-12-04 | BLEOMYCIN | 02 | N | 270022352 | CHLVPP/PABLOE |
| 270018478 | 270019292 | 1.84 | 112.4 | Neo-adjuvant (N) | 2018-04-20 | 2018-05-19 | CYCLOPHOSPHAMIDE | N | N | 270022508 | HYDROXYCARBAMIDE |
| 270018479 | 270010495 | 1.67 | null | Curative (C) | 2015-02-04 | 2015-09-02 | Alemtuz+Cyclophos+Fludara Allo | null | N | 270022551 | CISPLATIN + CETUXIMAB |
| 270018480 | 270010502 | 1.75 | 69.6 | Curative (C) | 2017-06-22 | 2017-06-30 | Methotrexate intrathecal | N | N | 270022647 | ECHELON 1 TRIAL |
| 270018481 | 270010504 | 1.82 | 67.3 | Curative (C) | 2018-06-11 | 2018-06-16 | Dacarbazine | 02 | N | 270022677 | CYCLOPHOSPHAMIDE |
| 270018482 | 270010516 | null | 112.4 | Disease modification (D) | 2018-06-14 | 2018-06-15 | R GDP | N | Y | 270022895 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 270018483 | 270010524 | 1.71 | 51.3 | Neo-adjuvant (N) | 2015-06-10 | 2015-07-23 | Dacarbazine | N | N | 270022984 | CVP R |
| 270018484 | 270010527 | 1.62 | 71.6 | Palliative (P) | 2017-02-26 | 2017-02-26 | RUXOLITINIB | 02 | N | 270022987 | ATG + BUSULFAN + FLUDARABINE |
| 270018486 | 270020164 | 1.63 | 58.2 | Disease modification (D) | 2018-06-07 | 2018-06-14 | Dacarbazine | 2 | N | 270023123 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 270018487 | 270010533 | null | 80.3 | Palliative (P) | 2017-11-30 | 2017-12-07 | NHL 2003 Gp B COPADM 1 & 2 | 02 | Y | 270023155 | IVE-R |
| 270018488 | 270010537 | null | 49.5 | Disease modification (D) | 2015-11-07 | 2016-01-09 | CHLORAMBUCIL + ETOPOSIDE + LOMUSTINE | N | Y | 270023156 | CYCLOPHOSPHAMIDE |
| 270018489 | 270010540 | null | 49.5 | Curative (C) | 2015-08-20 | 2017-01-21 | BENDAMUSTINE + CYTARABINE + RITUXIMAB | N | N | 270023166 | PMITCEBOM-R |